Women constitute an understudied yet important demographic for HIV vaccine acceptability research. In a systematic review of research on HIV vaccine acceptability, including general and mostat-risk populations in both developed and developing countries, 6 none of the 18 investigations applied quantitative methods to assess HIV vaccine acceptability among women.
Women in high-income countries are increasingly at risk for HIV. In North America, Black women, in particular, are at disproportionately high risk. In Ontario, the province with the highest number of persons living with HIV in Canada, the proportion of new HIV diagnoses per year among women has risen from approximately 10% in the mid-1990s to 18 .7% in 2009, having peaked in 2008 at 24.7%. 7 Available epidemiological data reveal that Black Ontarians (3.9% of the provincial population) 8 represented 9.7% of AIDS diagnoses reported from 1981-2004, including 7.4% of male and 38.5% of female diagnoses. 9 HIV prevalence data in Toronto reveal that from 1981-2004, Black Canadians represented 11.4% of male diagnoses and 55.1% of female diagnoses, constituting 17.1% of HIV diagnoses overall. 9 Similarly, in the US, African American women account for 57% of new HIV infections among all women, a rate 15 times higher than that among White women.
METHODS
"Sisters, Daughters, Mothers, and Aunties" was a communityuniversity collaboration between Women's Health in Women's Hands Community Health Centre (WHIWH) and the University of Toronto. 12 This community-based project was conducted under the guidance of a Community Advisory Board (CAB), composed of six diverse Black women who served as educators and advocates for the major African and Caribbean communities in Toronto. The CAB provided input on survey questionnaire items, sampling, recruitment, and interpretation of the data. We trained 12 peer research assistants from the communities who conducted recruitment, implemented the survey questionnaire, and entered and checked data.
This study received approval from the Research Ethics Board of the University of Toronto (Protocol ID 00016091). All participants provided written informed consent.
Recruitment
In collaboration with our community partner, WHIWH, and the CAB, we compiled a list of community organizations and health centres serving primarily African, Caribbean and other Black women in the Greater Toronto Area (GTA). Peer research assistants conducted recruitment through the identified organizations. Eligibility criteria included women in the GTA, 18 years of age or older, and self-identification as Black and of African, Caribbean or mixed origin.
Data collection
The survey questionnaire was constructed based on previous survey research on HIV vaccine acceptability among ethnic minority adults in Los Angeles 5 and formative qualitative research conducted with Black women from African and Caribbean communities that explored knowledge, attitudes and beliefs about HIV prevention and future HIV vaccines. 12, 13 We assessed socio-demographic variables, including age, place of birth, years in Canada, primary ethnic origin (African or Caribbean descent, or multiple backgrounds), income, education, relationship status and employment status.
Conjoint analysis
Conjoint analysis is a technique used for assessing consumer product preferences that has increasingly been applied to health care services and technologies. 14, 15 In this method, a hypothetical product is characterized by a set of defining attributes (e.g., efficacy), which can take on varying levels (e.g., 50%, 99%). A series of product scenarios are then created, which define the product by systematically designed combinations of attributes and levels. Study participants are then asked to select among the presented scenarios, requiring them to make tradeoffs between product attributes. As a decompositional approach, the importance of individual attributes can be determined from the presentation of a multiattribute product, which is more similar to how products are presented to consumers in the real world than a compositional approach based on a series of single-attribute questions. 15 We used conjoint analysis to measure participant preferences among different hypothetical HIV vaccines and to determine the impact of each vaccine attribute on overall vaccine acceptability scores. Participants rated the acceptability of each of 8 hypothetical vaccines on a 7-point Likert scale, from 1=definitely to 7=defi-nitely not accept vaccination. These ratings were reversed and standardized to a 100-point scale to improve interpretability, with higher scores indicating greater vaccine acceptability.
The hypothetical HIV vaccine scenarios combined the following 7 attributes: efficacy (99% vs. 50%), side effects (none vs. temporary aches and fevers), out-of-pocket cost ($10 vs. $250), duration of protection (10 years vs. 1 year), doses (1 vs. 4), cross-clade protection (Canadian and international strains vs. Canadian strains), and route of administration (oral vs. injection). These attributes were selected based on our formative qualitative research with women and community key informants 12 and review of the relevant literature. 16, 17 The attribute combinations that made up the 8 vaccine profiles were constructed using an 8-run (2 ) Plackett-Burman fractional factorial design. 18 As a methodological check, we included an additional calibration scenario with all attributes set to the levels hypothesized as preferred. The acceptability score from the calibration scenario is not included in the conjoint analysis.
Data analysis
Overall vaccine acceptability was calculated by assessing the mean acceptability for each participant across all 8 vaccine scenarios, then taking the mean score across participants. To calculate vaccine attribute impact on acceptability, the mean acceptability of the 4 scenarios with the non-preferred attribute level (e.g., minor side effects) is subtracted from the mean acceptability of the 4 scenarios with the preferred attribute level (e.g., no side effects); this difference is the impact of side effects on acceptability. If a particular attribute has no effect on acceptability, its impact on acceptability should equal zero. We used a 1-sample t-test to test whether the impact of each attribute significantly differed from zero.
We then tested overall vaccine acceptability for association with socio-demographic characteristics using Pearson correlation with continuous variables, t-tests with binary variables, and analysis of variance with categorical variables. Acceptability of the 8 vaccine scenarios was calculated by taking the mean acceptability across participants for each scenario. Because the attributes are dichotomous, each attribute impact score is mathematically equivalent to the corresponding coefficients in a multiple regression model that fits acceptability scores of the 8 hypothetical vaccines to the 7 attributes included as independent variables. 15 Calculating conjoint analysis impact scores using this method allows some of the flexibility of regression methods, namely, adjustment for possible socio-demographic confounders. We ran two multiple regression models, one that included socio-demographic characteristics that were associated with overall vaccine acceptability at the p<0.05 level, and another including those measures associated at the p<0.1 level. We then compared the adjusted impact scores with the unadjusted impact scores for differences.
RESULTS
Overall, 206 Black women of African and Caribbean descent completed the survey. Socio-demographic information is presented in Table 1 . Participants were of mean age 35 years (SD=11), with mean monthly income of $1,683 Canadian dollars (SD=1,456); the majority (81%) were born outside of Canada. Those born elsewhere had spent a mean of 18 years (SD=9) in Canada. The majority of the sample (52%) were of Caribbean ethnic heritage; 40% had completed high school, 42% were single/never married, and 40% were working full-time.
Acceptability of the 8 vaccines ranged from 82.1 (24.6) to 37.1 (SD=25.3). The overall mean level of HIV vaccine acceptability was 58.8 (SD=17.2) on the 100-point scale. Table 2 shows the mean HIV vaccine acceptability score by vaccine scenario, ordered from highest to lowest, and the corresponding attribute profiles of each vaccine. The highest-rated vaccine had the following attribute profile: 99% efficacy, no side effects, cost $10, 10-year protection, one dose, protection against Canadian-only strains and administered by injection.
The calibration scenario, with all attributes set to levels hypothesized to be preferred, had an acceptability score of 86.3 (23.4) . This was the highest score of all scenarios, which confirmed the selection of preference levels across attributes. This scenario was not included in conjoint analysis.
The impact of HIV vaccine attributes on acceptability is presented in Table 3 . Efficacy had the greatest impact on acceptability, with an impact score of 22.6 (SD=23.7, p<0.01). In decreasing order, side effects (8.6, SD=19.7, p<0.01), out-of-pocket cost (7.6, SD=16.3, p<0.01), duration of protection (6.5, SD=15.6, p<0.01), and number of doses (1.8, SD=10.34, p<0.05) had significant impacts on vaccine acceptability. Cross-clade protection and route of administration did not affect vaccine acceptability. Table 4 presents the association of overall mean HIV acceptability score with the sample socio-demographic characteristics. HIV vaccine acceptability significantly differed by ethnicity, relationship status, and employment status. Women of African descent had lower acceptability scores than women of Caribbean descent (-4.9, p=0.05). Single/never married women had lower scores than those who were married (-5.5, p=0.02) and those working part-time had lower scores than women working full-time, at home or on disability (p=0.03). Monthly income was positively correlated with HIV acceptability at a trend level of significance (p<0.064).
The impact of vaccine attributes on vaccine acceptability was virtually unchanged after adjusting for ethnicity, relationship status, and employment status. first study to quantify HIV vaccine acceptability, and the relative impact of vaccine attributes on acceptability, among Black women. Previous research similarly indicates that HIV vaccine acceptability is not guaranteed, even among populations with elevated rates of HIV diagnoses. 5, 6, 15 As Black women are a population at disproportionately high risk for HIV, it is important to identify vaccine attributes and other correlates of acceptability among this population in order to guide evidence-informed interventions to support future HIV vaccine uptake.
Among 7 HIV vaccine attributes, efficacy had the greatest impact on acceptability. A high efficacy vaccine would have moderately high acceptability, while a partial efficacy vaccine resulted in acceptability less than 50 on the 100-point scale. The primacy of efficacy in determining HIV vaccine acceptability is similar to findings among other populations, including ethnic minorities and other key populations in the US at higher risk of HIV exposure. 5 Nevertheless, the likelihood that initial HIV vaccines will not confer sterilizing immunity, unlike many existing childhood vaccines, suggests an important role for information and education about the benefits of partially efficacious vaccines as a component of combination prevention for Black women.
The impact of side effects on acceptability, the second most influential attribute, is similar to findings from previous research with African American women. 17, 19 Given mistrust of medical research based on past unethical experimentation involving Black communities, 13, 20 it may be important to directly address this mistrust and provide transparent information from trusted sources, including ethnospecific health care centres. 12 The significant impact of out-of-pocket cost on acceptability, a finding similar to previous studies among low-income US ethnic minority adults, 5 suggests a key role for public policy in supporting HIV vaccine uptake. Participants demonstrated tolerance for low out-of-pocket cost of $10, but were significantly less likely to accept a vaccine that cost $250. The positive correlations between employment status and income, respectively, and HIV vaccine acceptability further support the importance of financial considerations among an under-employed sample with average income less than $20,000 per year. Key populations at higher risk of HIV exposure are often low income; in Canada, Black women are among the most economically marginalized groups. 21 Given lifetime costs for HIV treatment in excess of $400,000, 22 HIV vaccine cost subsidies may prove a cost-effective public policy intervention. Qualitative studies with low-income Black Canadian 12, 18 and African American women 17, 19, 23 highlight concerns about HIV vaccine access in the context of out-of-pocket cost, stigma, and discrimination in the health care system. Accordingly, targeted structural interventions in health care policy, funding mechanisms and health care institutions may be an important component of future HIV vaccine rollout for Black women. 24 We found that ever being married was associated with higher overall HIV vaccine acceptability. Although higher vaccine acceptability among married women may be counterintuitive in light of assumptions that single women are at greater risk for HIV infection, particular risks for married, largely immigrant, women may result from gendered cultural traditions and financial dependence on male spouses 25 as well as stigma, all of which constrain women's ability to implement existing HIV preventive interventions, such as condom use and HIV testing.
12,13 HIV vaccines, though not without their own challenges, may obviate some of the barriers for women in negotiating male-controlled prevention technologies and products requiring pericoital use. 17 Finally, the lower levels of HIV vaccine acceptability among women of African versus Caribbean descent may be a function of the particular stigma associated with HIV among people from African communities. Stigma has been identified as a barrier to uptake of a broad array of HIV prevention and treatment interventions, including condom use, 26 HIV testing, 27 prevention of mother-to-child transmission 28 and antiretroviral therapy. 29 Thus while an HIV vaccine as a universal preventive intervention may help to mitigate the stigma of AIDS, that same stigma may function as a barrier to vaccine uptake. 6 Limitations to this study include the nonrandom sampling; the results may not be generalizable across Black Canadian women. We also did not assess differences among Black women by language, religion or sexual orientation. Nevertheless we implemented a broad recruitment strategy in collaboration with women from African, Caribbean and Black communities across the Greater Toronto Area; and we achieved a diverse sample of women by age, national origin and marital status -a population over-represented in HIV prevalence statistics, yet under-represented in research on new HIV prevention technologies. Additionally, we are only able to assess the impact of HIV vaccine attributes included in the conjoint scenarios; other attributes also may influence acceptability. Finally, by necessity, women assessed hypothetical HIV vaccines; acceptability may change once a vaccine is publicly available. However the purpose of this investigation was to anticipate and in turn mitigate challenges to future HIV vaccine roll-out.
CONCLUSIONS
Overall, this community-based investigation suggests several challenges to the acceptability of future HIV vaccines among Black women from African and Caribbean communities, some of which (e.g., partial efficacy) are similar to those among other populations and other challenges (e.g., ethnicity, marital status) that may be population-and subpopulation-specific. Educational interventions that explain the benefits of partially efficacious vaccines as a component of combination HIV prevention and clearly describe possible risks and side effects, along with structural interventions to subsidize out-of-pocket vaccine costs, may increase HIV vaccine uptake. Differences in acceptability within Black communities indicate that tailored interventions to address what may be distinct barriers to uptake among single and married women, and to support uptake among women from African communities may promote increased HIV vaccine coverage.
